Details of the Drug
General Information of Drug (ID: DM3INUK)
Drug Name |
GNF-PF-117
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-Hydroxy-6-methoxy-2-phenylquinoline; 17282-70-1; GNF-PF-117; 6-methoxy-2-phenylquinolin-4-ol; 6-Methoxy-2-phenyl-4-quinolinol; 6-Methoxy-2-phenyl-1H-quinolin-4-one; CHEMBL14120; 6-Methoxy-2-phenyl-quinolin-4-ol; Maybridge3_005419; AC1L3YAP; Oprea1_238017; SCHEMBL6534282; SCHEMBL10610678; CTK8F6034; CTK7A7980; MolPort-000-677-170; KUC100231N; HMS1446G07; ZINC8649323; 2-Phenyl-4-oxy-6-methoxy-chinolin; KUC100231; BDBM50041130; SBB016283; AKOS009868047; AKOS000273771; MCULE-6727803755; AB10684; CCG-252411; IDI1_016806
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 251.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||